Australian S1226 patent granted
SolAeroMed’s lead drug, S-1226, to treat asthma and other obstructive lung diseases now has issued patents in the EU, USA and most recenlty Australia. Details at https://www.google.com/patents/WO2007071052A1?cl=en&dq=2006329199&hl=en&…
SolAeroMed’s lead drug, S-1226, to treat asthma and other obstructive lung diseases is issued in throughout Europe. In the USA the US patent office awarded nearly 2 addtional years of patent life, in recognition of delays caused by negotiation.
SolAeroMed’s lead patent lawyer is Irene Bridger, Bennett Jones in Calgary, who has been working on our patents since inception.
In addition to S1226 IP, SolAeroMed is purusing IP related to S1226 device technology, and sister drug S-1229 to treat Acute Respiratory Distress with Prof Matthias Amrein. Details athttp://www.google.com/patents/WO2014047715A1?cl=en
John Dennis
CEO